SOLIFENACIN SUCCINATE - Generic Drug Details

✉ Email this page to a colleague

What are the generic drug sources for solifenacin succinate and what is the scope of freedom to operate?

Solifenacin succinate is the generic ingredient in three branded drugs marketed by Astellas, Accord Hlthcare, Ajanta Pharma Ltd, Alembic, Alkem Labs Ltd, Amneal Pharms Co, Annora Pharma, Aurobindo Pharma, Austarpharma, Breckenridge, Chartwell Rx, Cipla, Glenmark Pharms, Lannett Co Inc, Macleods Pharms Ltd, MSN, Qilu, Rising, Sciegen Pharms Inc, Strides Pharma, Sunshine, Teva Pharms Usa, Unichem, Watson Labs Inc, and Zydus Pharms, and is included in twenty-six NDAs. There is one patent protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Solifenacin succinate has twenty-three patent family members in twenty-one countries.

There are twenty-nine drug master file entries for solifenacin succinate. Twenty-seven suppliers are listed for this compound.

Summary for SOLIFENACIN SUCCINATE

International Patents:	23
US Patents:	1
Tradenames:	3
Applicants:	25
NDAs:	26
Drug Master File Entries:	29
Finished Product Suppliers / Packagers:	27
Raw Ingredient (Bulk) Api Vendors:	78
Clinical Trials:	58
Patent Applications:	4,502
Drug Prices:	Drug price trends for SOLIFENACIN SUCCINATE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SOLIFENACIN SUCCINATE
What excipients (inactive ingredients) are in SOLIFENACIN SUCCINATE?	SOLIFENACIN SUCCINATE excipients list
DailyMed Link:	SOLIFENACIN SUCCINATE at DailyMed

See drug prices for SOLIFENACIN SUCCINATE

Recent Clinical Trials for SOLIFENACIN SUCCINATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Longhua Hospital	N/A
Shanghai University of Traditional Chinese Medicine	N/A
Hikma Pharma	Phase 1

See all SOLIFENACIN SUCCINATE clinical trials

Pharmacology for SOLIFENACIN SUCCINATE

Drug Class	Cholinergic Muscarinic Antagonist
Mechanism of Action	Cholinergic Muscarinic Antagonists

Medical Subject Heading (MeSH) Categories for SOLIFENACIN SUCCINATE

Muscarinic Antagonists
Urological Agents

Anatomical Therapeutic Chemical (ATC) Classes for SOLIFENACIN SUCCINATE

G04BD	Drugs for urinary frequency and incontinence
G04B	UROLOGICALS
G04	UROLOGICALS
G	Genito-urinary system and sex hormones

Paragraph IV (Patent) Challenges for SOLIFENACIN SUCCINATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VESICARE LS	Oral Suspension	solifenacin succinate	1 mg/mL	209529	1	2021-05-27
VESICARE	Tablets	solifenacin succinate	5 mg and 10 mg	021518	1	2009-04-08

US Patents and Regulatory Information for SOLIFENACIN SUCCINATE

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Accord Hlthcare	SOLIFENACIN SUCCINATE	solifenacin succinate	TABLET;ORAL	207477-001	Jan 4, 2022		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Qilu	SOLIFENACIN SUCCINATE	solifenacin succinate	TABLET;ORAL	209333-002	May 20, 2019	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Qilu	SOLIFENACIN SUCCINATE	solifenacin succinate	TABLET;ORAL	209333-001	May 20, 2019	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Zydus Pharms	SOLIFENACIN SUCCINATE	solifenacin succinate	TABLET;ORAL	207721-002	Oct 19, 2020		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Amneal Pharms Co	SOLIFENACIN SUCCINATE	solifenacin succinate	TABLET;ORAL	209719-002	May 20, 2019		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for SOLIFENACIN SUCCINATE

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Astellas	VESICARE	solifenacin succinate	TABLET;ORAL	021518-001	Nov 19, 2004	⤷ Sign Up	⤷ Sign Up
Astellas	VESICARE	solifenacin succinate	TABLET;ORAL	021518-002	Nov 19, 2004	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for SOLIFENACIN SUCCINATE

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
European Patent Office	2572717	COMPOSITION PHARMACEUTIQUE CONTENANT DE LA SOLIFÉNACINE (PHARMACEUTICAL COMPOSITION CONTAINING SOLIFENACIN)	⤷ Sign Up
Japan	WO2011145642	ソリフェナシン含有医薬組成物	⤷ Sign Up
China	102905706	Pharmaceutical composition containing solifenacin	⤷ Sign Up
Canada	2799942	COMPOSITION PHARMACEUTIQUE CONTENANT DE LA SOLIFENACINE (PHARMACEUTICAL COMPOSITION CONTAINING SOLIFENACIN)	⤷ Sign Up
South Korea	20130093010	PHARMACEUTICAL COMPOSITION CONTAINING SOLIFENACIN	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

Supplementary Protection Certificates for SOLIFENACIN SUCCINATE

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0801067	SPC/GB04/029	United Kingdom	⤷ Sign Up	PRODUCT NAME: SOLIFENACIN AND/OR PHARMACEUTICALLY ACTIVE SALT THEREOF; REGISTERED: NL RVG 29151 20031216; NL RVG 29152 20031216; UK PL 00166/0197 20040816; UK PL 0016/0198 20040816
0801067	04C0032	France	⤷ Sign Up	PRODUCT NAME: SUCCINATE DE SOLIFENACINE; NAT. REGISTRATION NO/DATE: NL 30 109 20040816; FIRST REGISTRATION: NL - RVG 29 151 20031216
0801067	C00801067/01	Switzerland	⤷ Sign Up	PRODUCT NAME: SOLIFENACIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 57203 12.05.2006
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.